| content |
Androgen receptor
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Androgen_receptor".
|
Androgen receptor
|
 |
| Structure of the ligand binding domain of the androgen receptor (rainbow cartoon) complexed with testosterone (white sticks) based on PDB 2AM9. |
| Available structures: 1e3g, 1gs4, 1i37, 1i38, 1r4i, 1t5z, 1t63, 1t65, 1t73, 1t74, 1t76, 1t79, 1t7f, 1t7m, 1t7r, 1t7t, 1xj7, 1xnn, 1xow, 1xq3, 1z95, 2am9, 2ama, 2amb, 2ao6, 2ax6, 2ax7, 2ax8, 2ax9, 2axa, 2ihq, 2nw4, 2oz7 |
| Identifiers |
| Symbols |
AR; AIS; DHTR; HUMARA; KD; NR3C4; SBMA; SMAX1; TFM |
| External IDs |
OMIM: 313700 MGI: 88064 HomoloGene: 28 |
|
|
| RNA expression pattern |
|


More reference expression data
|
| Orthologs |
|
Human |
Mouse |
| Entrez |
367 |
11835 |
| Ensembl |
ENSG00000169083 |
ENSMUSG00000046532 |
| Uniprot |
P10275 |
P19091 |
| Refseq |
NM_000044 (mRNA)
NP_000035 (protein) |
NM_013476 (mRNA)
NP_038504 (protein) |
| Location |
Chr X: 66.68 - 66.87 Mb |
Chr X: 94.35 - 94.52 Mb |
| Pubmed search |
[1] |
[2] |
The androgen receptor (AR), also known as NR3C4 (nuclear receptor subfamily 3, group C, member 4), is a type of nuclear receptor[1] which is activated by binding of either of the androgenic hormones testosterone or dihydrotestosterone.[2] The androgen receptor is most closely related to the progesterone receptor, and progestins in higher dosages can block the androgen receptor.[3][4]
The main function of the androgen receptor is as a DNA binding transcription factor which regulates gene expression;[5] however, the androgen receptor has other functions as well.[6] Androgen regulated genes are critical for the development and maintenance of the male sexual phenotype.
Function
Androgenic hormones and their effect on development
In some cell types testosterone interacts directly with androgen receptors while in others testosterone is converted by 5-alpha-reductase to dihydrotestosterone, an even more potent agonist for androgen receptor activation.[7] Testosterone appears to be the primary androgen receptor activating hormone in the Wolffian duct while dihydrotestosterone is the main androgenic hormone in the urogenital sinus, urogenital tubercle, and hair follicles.[8] Hence testosterone is primarily responsible for the development of male primary sexual characteristics while dihydrotestosterone is responsible for secondary male characteristics.
Androgens cause slow epiphysis, or maturation of the bones, but more of the potent epiphysis effect comes from the estrogen produced by aromatization of androgens. Steroid users of teen age may find that their growth had been stunted by androgen and/or estrogen excess. People with too little sex hormones can be short during puberty but end up taller as adults as in androgen insensitivity syndrome or estrogen insensitivity syndrome.[9]
Mechanism of androgen receptor action
Genomic
The primary mechanism of action for androgen receptors is direct regulation of gene transcription. The binding of an androgen to the androgen receptor results in a conformational change in the receptor which in turn causes dissociation of heat shock proteins, transport from the cytosol into the cell nucleus, and dimerization. The androgen receptor dimer binds to a specific sequence of DNA known as a hormone response element. Androgen receptors interact with other proteins in the nucleus resulting in up or down regulation of specific gene transcription.[10] Up-regulation or activation of transcription results in increased synthesis of messenger RNA which in turn is transcribed by ribosomes to produce specific proteins. One of the known target genes of androgen receptor activation is insulin-like growth factor I (IGF-1).[11] Thus, changes in levels of specific proteins in cells is one way that androgen receptors control cell behavior.
Non-genomic
More recently, androgen receptors have been shown to have a second mode of action. As has been also found for other steroid hormone receptors such as estrogen receptors, androgen receptors can have actions that are independent of their interactions with DNA.[6][12] Androgen receptors interact with certain signal transduction proteins in the cytoplasm. Androgen binding to cytoplasmic androgen receptors can cause rapid changes in cell function independent of changes in gene transcription, such as changes in ion transport. Regulation of signal transduction pathways by cytoplasmic androgen receptors can indirectly lead to changes in gene transcription, for example, by leading to phosphorylation of other transcription factors.
One function of androgen receptor that is independent of direct binding to its target DNA sequence, is facilitated by recruitment via other DNA binding proteins. One example is serum response factor, a protein which activates several genes that cause muscle growth.[13]
Genetics
Gene
The AR gene for the androgen receptor is located on the X chromosome at Xq11-12.[14][15]
AR deficiencies
The androgen insensitivity syndrome, formerly known as testicular feminization, is caused by a mutation of the Androgen Receptor gene located on the X chromosome (locus:Xq11-Xq12).[16] The androgen receptor seems to affect neuron physiology and is defective in Kennedy disease.[17][18] In addition, point mutations and trinucleotide repeat polymorphisms has been linked to a number of additional disorders.[19]
Structure
Structural domains of the two isoforms (AR-A and AR-B) of the human androgen receptor. Numbers above the bars refer to the amino acid residues which separate the domains starting from the N-terminus (left) to C-terminus (right). NTD = N-terminal domain, DBD = DNA binding domain. LBD = ligand binding domain. AF = activation function.
Isoforms
Two isoforms of the androgen receptor (A and B) have been identified:[20]
- AR-A - 87 kDa - N-terminus truncated (lacks the first 187 amino acids)
- AR-B - 110 kDa - full length
Domains
Like other nuclear receptors, the androgen receptor is modular in structure and is comprised of the following functional domains labeled A through F:[21]
- A/B) - N-terminal regulatory domain contains:[22]
- activation function 1 (AF-1) between residues 101 and 370 required for full ligand activated transcriptional activity
- activation function 5 (AF-5) between residues 360-485 is responsible for the constitutive activity (activity without bound ligand)
- dimerization surface involving residues 1-36 (containing the FXXLF motif where F = phenylalanine, L = leucine, and X = any amino acid residue) and 370-494 which both interact with the LBD in an intramolecular[23][24][25] head-to-tail interaction[26][27][28]
- C) - DNA binding domain (DBD)
- D) - Hinge region - flexible region that connects the DBD with the LBD; along with the DBD, contains a ligand dependent nuclear localization signal[29]
- E) - Ligand binding domain (LBD) containing
- activation function 2 (AF-2), responsible for agonist induced activity (activity in the presence of bound agonist)
- AF-2 binds either the N-terminal FXXFL motif intramolecularly or coactivator proteins (containing the LXXLL or preferably FXXFL motifs)[28]
- A ligand dependent nuclear export signal[30]
- F) - C-terminal domain
References
- ^ Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA (December 2006). "International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors". Pharmacol. Rev. 58 (4): 782–97. doi:10.1124/pr.58.4.9. PMID 17132855.
- ^ Roy AK, Lavrovsky Y, Song CS, Chen S, Jung MH, Velu NK, Bi BY, Chatterjee B (1999). "Regulation of androgen action". Vitam. Horm. 55: 309–52. PMID 9949684.
- ^ Bardin CW, Brown T, Isomaa VV, Jänne OA (1983). "Progestins can mimic, inhibit and potentiate the actions of androgens". Pharmacol. Ther. 23 (3): 443–59. PMID 6371845.
- ^ Raudrant D, Rabe T (2003). "Progestogens with antiandrogenic properties". Drugs 63 (5): 463–92. PMID 12600226.
- ^ Mooradian AD, Morley JE, Korenman SG (1987). "Biological actions of androgens". Endocr. Rev. 8 (1): 1–28. PMID 3549275.
- ^ a b Heinlein CA, Chang C (2002). "The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions". Mol. Endocrinol. 16 (10): 2181–7. doi:10.1210/me.2002-0070. PMID 12351684.
- ^ Davison SL, Bell R (April 2006). "Androgen physiology". Semin. Reprod. Med. 24 (2): 71–7. doi:10.1055/s-2006-939565. PMID 16633980.
- ^ Sinisi AA, Pasquali D, Notaro A, Bellastella A (2003). "Sexual differentiation". J. Endocrinol. Invest. 26 (3 Suppl): 23–8. PMID 12834017.
- ^ Frank GR (September 2003). "Role of estrogen and androgen in pubertal skeletal physiology". Med. Pediatr. Oncol. 41 (3): 217–21. doi:10.1002/mpo.10340. PMID 12868122.
- ^ Heemers HV, Tindall DJ (December 2007). "Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex". Endocr. Rev. 28 (7): 778–808. doi:10.1210/er.2007-0019. PMID 17940184.
- ^ Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, Belfiore A (March 2005). "Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells". Cancer Res. 65 (5): 1849–57. doi:10.1158/0008-5472.CAN-04-1837. PMID 15753383.
- ^ Fix C, Jordan C, Cano P, Walker WH (2004). "Testosterone activates mitogen-activated protein kinase and the cAMP response element binding protein transcription factor in Sertoli cells". Proc Natl Acad Sci USA 101 (30): 10919–24. doi:10.1073/pnas.0404278101. PMID 15263086.
- ^ Vlahopoulos S, Zimmer WE, Jenster G, Belaguli NS, Balk SP, Brinkmann AO, Lanz RB, Zoumpourlis VC, Schwartz RJ (2005). "Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene". J. Biol. Chem. 280 (9): 7786–92. doi:10.1074/jbc.M413992200. PMID 15623502.
- ^ Chang CS, Kokontis J, Liao ST (1988). "Molecular cloning of human and rat complementary DNA encoding androgen receptors". Science 240 (4850): 324–6. doi:10.1126/science.3353726. PMID 3353726.
- ^ Trapman J, Klaassen P, Kuiper GG, van der Korput JA, Faber PW, van Rooij HC, Geurts van Kessel A, Voorhorst MM, Mulder E, Brinkmann AO (1988). "Cloning, structure and expression of a cDNA encoding the human androgen receptor". Biochem. Biophys. Res. Commun. 153 (1): 241–8. PMID 3377788.
- ^ Brown TR (1995). "Human androgen insensitivity syndrome" (abstract). J. Androl. 16 (4): 299–303. PMID 8537246.
- ^ Kennedy WR, Alter M, Sung JH (1968). "Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait". Neurology 18 (7): 671–80. PMID 4233749.
- ^ Yu Z, Dadgar N, Albertelli M, Gruis K, Jordan C, Robins DM, Lieberman AP (2006). "Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model". J. Clin. Invest. 116 (10): 2663–72. doi:10.1172/JCI28773. PMID 16981011.
- ^ Rajender S, Singh L, Thangaraj K (2007). "Phenotypic heterogeneity of mutations in androgen receptor gene". Asian J. Androl. 9 (2): 147–79. doi:10.1111/j.1745-7262.2007.00250.x. PMID 17334586.
- ^ Wilson CM, McPhaul MJ (1994). "A and B forms of the androgen receptor are present in human genital skin fibroblasts". Proc. Natl. Acad. Sci. U.S.A. 91 (4): 1234–8. doi:10.1073/pnas.91.4.1234. PMID 8108393.
- ^ Brinkmann AO, Klaasen P, Kuiper GG, van der Korput JA, Bolt J, de Boer W, Smit A, Faber PW, van Rooij HC, Geurts van Kessel A, Voorhorst MM, Mulder E, Trapman J (1989). "Structure and function of the androgen receptor". Urol. Res. 17 (2): 87–93. PMID 2734982.
- ^ Jenster G, van der Korput HA, Trapman J, Brinkmann AO (1995). "Identification of two transcription activation units in the N-terminal domain of the human androgen receptor". J. Biol. Chem. 270 (13): 7341–6. doi:10.1074/jbc.270.13.7341. PMID 7706276.
- ^ Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma AA, Miner JN, Diamond MI (July 2005). "The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions". Proc. Natl. Acad. Sci. U.S.A. 102 (28): 9802–7. doi:10.1073/pnas.0408819102. PMID 15994236.
- ^ Klokk TI, Kurys P, Elbi C, Nagaich AK, Hendarwanto A, Slagsvold T, Chang CY, Hager GL, Saatcioglu F (March 2007). "Ligand-specific dynamics of the androgen receptor at its response element in living cells". Mol. Cell. Biol. 27 (5): 1823–43. doi:10.1128/MCB.01297-06. PMID 17189428.
- ^ van Royen ME, Cunha SM, Brink MC, Mattern KA, Nigg AL, Dubbink HJ, Verschure PJ, Trapman J, Houtsmuller AB (April 2007). "Compartmentalization of androgen receptor protein-protein interactions in living cells". J. Cell Biol. 177 (1): 63–72. doi:10.1083/jcb.200609178. PMID 17420290.
- ^ Langley E, Zhou ZX, Wilson EM (1995). "Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer". J. Biol. Chem. 270 (50): 29983–90. doi:10.1074/jbc.270.50.29983. PMID 8530400.
- ^ Berrevoets CA, Doesburg P, Steketee K, Trapman J, Brinkmann AO (1998). "Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2)". Mol. Endocrinol. 12 (8): 1172–83. doi:10.1210/me.12.8.1172. PMID 9717843.
- ^ a b Dubbink HJ, Hersmus R, Verma CS, van der Korput HA, Berrevoets CA, van Tol J, Ziel-van der Made AC, Brinkmann AO, Pike AC, Trapman J (2004). "Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor". Mol. Endocrinol. 18 (9): 2132–50. doi:10.1210/me.2003-0375. PMID 15178743.
- ^ Kaku N, Matsuda KI, Tsujimura A, Kawata M (April 2008). "Characterization of nuclear import of the domain-specific androgen receptor in association with the importin α/β and Ran-GTP systems". Endocrinology 149: 3960. doi:10.1210/en.2008-0137. PMID 18420738.
- ^ Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, Wang Z (October 2003). "Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor". J. Biol. Chem. 278 (43): 41998–2005. doi:10.1074/jbc.M302460200. PMID 12923188.
See also
External links
|
Transcription factors and intracellular receptors |
|
|
(1) Basic domains |
|
|
|
Activating transcription factor ( AATF, 1, 2, 3, 4, 5, 6, 7) • AP-1 ( c-Fos, FOSB, FOSL1, FOSL2, c-Jun, JUNB, JUND) • BACH ( 1, 2) • BATF • BLZF1 • C/EBP ( α, β, γ, δ, ε, ζ) • CREB ( 1, 3, L1) • CREM • DBP • DDIT3 • GABPA • HLF • MAF ( B, F, G, K) • NFE ( 2, L1, L2) • NRL • NRF1 • XBP1
|
|
(1.2) Basic helix-loop-helix ( bHLH)
|
ATOH1 • AhR • AHRR • ARNT • ASCL1 • BHLHB2 • BMAL ( ARNTL, ARNTL2) • CLOCK • EPAS1 • HAND ( 1, 2) • HES ( 5, 6) • HEY ( 1, 2, L) • HES1 • HIF ( 1A, 3A) • ID ( 1, 2, 3, 4) • LYL1 • MXD4 • MYCL1 • MYCN • Myogenic regulatory factors ( MyoD, Myogenin, MYF5, MYF6) • Neurogenins • NeuroD ( 1, 2) • NPAS ( 1, 2, 3) • OLIG ( 1, 2) • Scleraxis • TAL1 • Twist • USF1
|
|
|
|
|
|
|
(1.4) NF-1
|
|
|
|
(1.5) RF-X
|
|
|
|
(1.6) Basic helix-span-helix (bHSH)
|
|
|
|
|
|
(2) Zinc finger DNA-binding domains |
|
|
|
subfamily 1 ( Thyroid hormone ( α, β), CAR, FXR, LXR ( α, β), PPAR ( α, β/δ, γ), PXR, RAR ( α, β, γ), ROR ( α, β, γ), Rev-ErbA ( α, β), VDR)
subfamily 2 ( COUP-TF ( I, II), Ear-2, HNF4 ( α, γ), PNR, RXR ( α, β, γ), Testicular receptor ( 2, 4), TLX)
subfamily 3 ( Steroid hormone ( Androgen, Estrogen ( α, β), Glucocorticoid, Mineralocorticoid, Progesterone), Estrogen related ( α, β, γ))
subfamily 4 NUR ( NGFIB, NOR1, NURR1) • subfamily 5 ( LRH-1, SF1) • subfamily 6 ( GCNF) • subfamily 0 ( DAX1, SHP)
|
|
|
(2.2) Other Cys4
|
|
|
|
(2.3) Cys2His2
|
General transcription factors ( TFIIA, TFIIB, TFIID, TFIIE, TFIIF ( 1, 2), TFIIH ( 1, 2, 4, 2I, 3A, 3C1, 3C2))
ATBF1 • BCL ( 6, 11A, 11B) • CTCF • E4F1 • EGR ( 2, 3) • ERV3 • GFI1 • GLI-Krüppel family ( 1, 2, 3, S2, YY1) • HIC ( 1, 2) • HIVEP ( 1, 2, 3) • IKZF ( 1, 2, 3) • ILF ( 2, 3) • KLF ( 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 17 ) • MTF1 • MYT1 • OSR1 • SP ( 1, 2, 4, 7) • Zbtb7 ( 7A, 7B) • ZBTB ( 16, 17, 20, 32, 33, 40) • zinc finger ( 3, 7, 9, 10, 19, 22, 24, 33B, 34, 35, 41, 43, 44, 51, 74, 143, 146, 148, 165, 202, 217, 219, 238, 239, 259, 267, 268, 281, 295, 318, 330, 346, 350, 365, 366, 384, 423, 451, 452, 471, 593, 638, 649, 655)
|
|
|
(2.4) Cys6
|
|
|
|
(2.5) Alternating composition
|
|
|
|
|
|
(3) Helix-turn-helix domains |
|
|
|
ARX • CDX ( 1, 2) • CRX • CUTL1 • DLX ( 3, 4, 5) • EMX2 • EN ( 1, 2) • FHL ( 1, 2, 3) • HESX1 • HHEX • HLX • Homeobox ( A1, A3, A4, A5, A7, | | | | |